Telix Americas has announced its new CEO, Kevin Richardson, and that it has dosed the final patient and completed recruitment for the phase III study "Zirconium in Renal Cancer Oncology (ZIRCON)" of its investigational renal cancer imaging agent TLX250-CDx.
Kevin Richardson.TLX250-CDX is being developed as an imaging agent to characterize indeterminate renal masses previously identified on CT or MRI as clear cell renal cell cancer (ccRCC) or non-ccRCC. Telix expects to report the outcome of the study in the second half of 2022.
Telix America's new CEO, Kevin Richardson, is a business leader with 25 years of experience within the healthcare industry. Most recently, Kevin was the chief operating officer of UroShape Medical. Prior to his position at UroShape, he spent seven years in the America's division of Sirtex Medical. Kevin oversaw a fivefold increase in sales for the U.S. region throughout his tenure, first as head of sales and then in the role of general manager and CEO of the America's division.
Kevin has also held senior sales positions at St Jude Medical and Boston Scientific. He holds a Master of Business Administration degree from the University of Texas. Kevin Richardson begins as CEO on July 11.
